28077790 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Levis, M,
Nguyen, B,
Williams, AB,
Small, D,
Brown, P,
Li, L,
Young, DJ,
Ma, H
|
Oncotarget |
2017 |
23392356 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Yu, C,
Albers, C,
Verbeek, M,
Duyster, J,
Leischner, H,
Illert, AL,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2013 |
22354205 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
Pearson, AD,
Avery, S,
Workman, P,
Faisal, A,
Mair, D,
Atrash, B,
Blagg, J,
Bavetsias, V,
Linardopoulos, S,
Mirabella, F,
Valenti, M,
Eccles, SA,
Moore, AS,
de Haven Brandon, A,
Sun, C,
Swansbury, J,
Gonzalez de Castro, D,
Raynaud, FI
|
Leukemia |
2012 |
23969938 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
Mullighan, CG,
Baker, SD,
Rubnitz, JE,
Zimmerman, EI,
Orwick, S,
Inaba, H,
Neale, GA,
Zatechka, DS,
Buaboonnam, J,
Enemark, EJ,
Shurtleff, S,
Wang, YD,
Olsen, SR
|
Clin. Cancer Res. |
2013 |
24227820 |
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Levis, M,
Small, D,
Cortes, J,
Ramachandran, A,
Galanis, A,
Rajkhowa, T,
Ma, H
|
Blood |
2014 |